Interpace Diagnostics Group, Inc. (58) | Note Agreements (3)
- Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021 (Filed With SEC on May 11, 2021)
- Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021 (Filed With SEC on May 11, 2021)
- Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc (Filed With SEC on July 19, 2019)
